Kidney Diseases: all 3,843 studies
Page 38 of 39. Open to participants first (492), then studies with results posted, then the rest; newest registration first within each.
- Kidney Disease BiomarkersCompletedNCT00255398
- Study for the Effectiveness of Intensive Therapy Aiming at a Remission of Diabetic NephropathyCompletedNCT00253786Not applicable
- Transplant and Addiction Project (TAP) - 1CompletedNCT00249652Phase 1/2
- Study Comparing Cyclosporin Dose Reduction With Cyclosporin Elimination in Kidney Transplant Recipients Taking SirolimusCompletedNCT00248313Phase 3
- The Effects of Acetylcysteine on Alleviating Damage of Oxidative Stress in Hemodialysis PatientsStatus unknownNCT00247507Phase 4
- The Effects of Obesity and Protein Intake on the KidneyCompletedNCT00244790Not applicable
- Defining The Role Of Dialysate Magnesium In Arrhythmogenicity On DialysisCompletedNCT00242164Phase 2
- Maximizing the Benefit of Renin-Angiotensin Blocking Drugs in Diabetic Renal Disease.CompletedNCT00240019Not applicable
- Cohort Study to Determine the Long-Term Safety and Efficacy of Biogeneric Epoetin Treatment for Renal AnemiaStatus unknownNCT00238043Phase 3
- Environmental Exposure to Lead and Progressive Renal Insufficiency in Type II Diabetic NephropathyCompletedNCT00237952Not applicable
- Contrast Nephropathy Prevention With N-Acetylcysteine in Acute Myocardial InfarctionCompletedNCT00237614Phase 2/3
- Pulse Wave Velocity, Pulse Wave Morphology and Blocking of the Reninangiotensin System in Patients With Chronic Kidney DiseaseStatus unknownNCT00235287Phase 4
- Efficacy and Safety of Lanthanum Carbonate in Reducing Serum Phosphorus Levels in Subjects With Stage 3 and 4 Chronic Kidney DiseaseCompletedNCT00234702Phase 2
- The Effect of Fructose on Blood Fats in Dialysis Patients and Healthy VolunteersCompletedNCT00234156Not applicable
- The Canadian Prevention of Renal and Cardiovascular Endpoints TrialCompletedNCT00231803Not applicable
- Peginesatide for Anemia in Chronic Hemodialysis PatientsCompletedNCT00228449Phase 2
- Safety, PD & PK of Multiple Doses of Peginesatide for Anemia in Chronic Kidney Disease PatientsCompletedNCT00228436Phase 2
- Vascular Reactivity in Kidney Disease PatientsCompletedNCT00226902Not applicable
- Effect of Strict Blood Pressure Control and ACE-Inhibition on Progression of Chronic Renal Failure in Pediatric PatientsCompletedNCT00221845Phase 3
- High Dose Ace Inhibitor Therapy Versus Combination of ACE and ARB TherapyCompletedNCT00212901Not applicable
- A Study of Four Dosing Regimens of PROCRIT (Epoetin Alfa) in Patients With Chronic Kidney Disease. Protocol Addendum: Extension Study of Maintenance Therapy of PROCRIT (Epoetin Alfa) in Patients With Chronic Kidney Disease.CompletedNCT00212875Phase 2
- EPIC(Effect of PhosLo on Phosphorus Levels in Chronic Kidney Disease)CompletedNCT00211978Phase 3
- A Study of Risk Factors for Anti-erythropoietin Antibody Positive Pure Red Cell Aplasia Among Patients With Chronic Kidney Disease Receiving Epoetin AlfaCompletedNCT00211068
- Alternate Dosing - Initiation of Every 2 Week Epoetin Alfa (PROCRIT) in the Treatment of Anemia.CompletedNCT00210743Phase 2
- Intravenous Iron in Patients With Anemia of Chronic Kidney DiseaseStatus unknownNCT00204256Phase 4
- Mycophenolate Mofetil (MMF): A Long-Term Data EvaluationCompletedNCT00203671
- Iron Sucrose in Stage 3/4 Kidney DiseaseCompletedNCT00202345Phase 3
- Statins in Proteinuric NephropathiesCompletedNCT00199927Phase 3
- Study of Safety and Efficacy of Renagel® Compared With Calcium Acetate in Patients With Peritoneal DialysisCompletedNCT00196755Phase 3
- Effect of Growth Hormone on Leptin, Cytokines and Body Composition of Children With Growth Failure Due to Chronic Kidney DiseaseTerminatedNCT00194961Phase 4
- The Fish and Fruit Study: Trial of Fish and Fruit to Improve Survival of Aboriginal People With End Stage Renal DiseaseCompletedNCT00192543Phase 3
- Kanagawa Valsartan Trial (KVT): Effects of Valsartan on Renal and Cardiovascular DiseaseCompletedNCT00190580Phase 4
- A Multi-Center, Observational Registry of Subjects With Secondary Hyperparathyroidism (HPT) and Chronic Kidney Disease (CKD)CompletedNCT00189501
- Pilot Study on the Use of Sirolimus to Treat Chronic Allograft Nephropathy in Children After Kidney TransplantCompletedNCT00188955Phase 4
- Olmesartan Medoxomil in Diabetes MellitusCompletedNCT00185159Phase 3
- Growth Hormone Treatment in Infants Aged 1 to 2 Years With Chronic Renal Insufficiency (CRI) and Growth Retardation.CompletedNCT00184769Phase 4
- Growth Hormone Treatment in Adult Patients With Chronic Kidney DiseaseCompletedNCT00184652Phase 2
- Cohort Study Comparing Short Daily Hemodialysis (HD) With Conventional HDWithdrawnNCT00182156
- Pilot Bleeding Study: Risk and Protective Factors Associated With Bleeding in the Hemodialysis PopulationStatus unknownNCT00182117
- Prevention and Treatment of Hemodialysis Vascular Access MalfunctionWithdrawnNCT00179192Phase 2
- Trial Comparing Care in Multiple Clinics Versus Care in a Cardiac, Diabetes and Kidney Care ClinicCompletedNCT00175721Not applicable
- Prevention of Contrast-Induced NephropathyCompletedNCT00175227Not applicable
- Active Vitamin D Effect on Left Ventricular HypertrophyTerminatedNCT00175149Phase 4
- Interferon Treatment for Patients With Chronic Hepatitis C and End Stage Renal DiseaseCompletedNCT00172809Phase 4
- Antialbuminuric Effects of Valsartan and LisinoprilTerminatedNCT00171600Phase 4
- Antiproteinuric Effect of Valsartan and LisinoprilCompletedNCT00171574Phase 4
- Brain Natriuretic Peptide (BNP) to Preserve Renal Function in Hospitalized Patients With Heart FailureCompletedNCT00170183Phase 3
- Comparison of Sirolimus to Tacrolimus for Long Term Therapy in Kidney Transplant With no SteroidsCompletedNCT00170053Phase 1
- Anti-Inflammatory Effects of Rosiglitazone in Patients With Stage 4 and 5 Chronic Kidney DiseaseWithdrawnNCT00169923Phase 2/3
- A Prospective, Randomised, Double-blind, Double-dummy, Forced-titration, Multicentre, Parallel Group, One Year Treatment Trial to Compare Telmisartan (MICARDIS) 80 mg Versus Losartan (COZAAR) 100 mg, in Hypertensive Type 2 Diabetic Patients With Overt Nephropathy (AMADEO Study)CompletedNCT00168857Phase 4
- Impact of Immunosuppressive Regimens on Polyomavirus-related Transplant NephropathyCompletedNCT00160966Phase 4
- Study to Evaluate the Efficacy and Safety of Daglutril Compared to Placebo on Top of Losartan in Type 2 Diabetics With Overt Nephropathy and Well Controlled HypertensionCompletedNCT00160225Phase 2
- Hemofiltration for Contrast-Induced NephropathyStatus unknownNCT00158080Not applicable
- Long Study - Longitudinal Thrombosis in End Stage Renal DiseaseStatus unknownNCT00157664
- Access II - Trial of Warfarin to Prevent Malfunction of Haemodialysis CathetersCompletedNCT00157651Phase 3
- Renal and Systemic Effects of NCX4016 in Patients With Type 2 Diabetes and Early NephropathyTerminatedNCT00157508Phase 2
- Epoetin Alfa (EPO) in Subjects With Chronic Kidney Disease (CKD)TerminatedNCT00156962Phase 3
- EPO Deep Tank in Dialysis SubjectsCompletedNCT00156949Phase 3
- Effects of Cognitive-Behavioral Therapy on Sleep Disturbance in Peritoneal Dialysis PatientsStatus unknownNCT00155441Phase 3
- Efficacy of Pentoxifylline on Chronic Kidney DiseaseCompletedNCT00155246Phase 4
- Prevalence of Proteinuria and Chronic Kidney Disease in Pediatric HIV-Infected PatientsCompletedNCT00153621
- INNOVATION Study - Telmisartan (Micardis) in Incipient Diabetic NephropathyCompletedNCT00153088Phase 4
- 1 Year Trial Telmisartan 80 mg Versus Valsartan 160 mg in Hypertensive Type 2 Diabetic Patients With Overt NephropathyCompletedNCT00153023Phase 4
- Efficacy of Epoetin Alfa Deep Tank in Treatment of Anemia in Patients With Chronic Kidney Disease Receiving HemodialysisCompletedNCT00146224Phase 3
- Use of Atorvastatin (Lipitor) to Decrease Panel Reactive Antibody TitersCompletedNCT00143741Phase 1
- A Randomized Control Trial Comparing Single vs. Multiple Application of Lidocaine Analgesia Prior to Urethral Catheterization ProceduresCompletedNCT00142064Phase 2
- Antiproteinuric Efficacy of Losartan Potassium in Patients With Non-Diabetic Proteinuric Renal Diseases (0954-213)CompletedNCT00140985Phase 4
- Nitric Oxide (NO) Activity and Diabetic NephropathyCompletedNCT00136188Phase 2/3
- Mycophenolate Mofetil in Membranous NephropathyCompletedNCT00135967Phase 2/3
- Treatment of Patients With Idiopathic Membranous NephropathyCompletedNCT00135954Phase 3
- START: Sensipar Treatment Algorithm to Reach K/DOQI Targets in Chronic Kidney Disease Subjects With Secondary HyperparathyroidismCompletedNCT00132431Phase 4
- Study to Evaluate the Performance and Safety of Expedial and Compare it to Expanded Polytetrafluoroethylene (ePTFE) Vascular Access GraftsTerminatedNCT00131872Phase 2
- Effect of Sulodexide in Overt Diabetic NephropathyTerminatedNCT00130312Phase 4
- An Evaluation of Aranesp® in Subjects With Anaemic Chronic Kidney Disease (CKD)CompletedNCT00124098Phase 3
- Study of Safety and Efficacy of Doxercalciferol in Patients With Chronic Kidney Disease, Stage 3 or 4, and Secondary HyperparathyroidismCompletedNCT00123461Phase 4
- Efficacy Study: Darbepoetin Alfa for the Treatment of Anemia in Patients With Chronic Kidney DiseaseCompletedNCT00121602Phase 3
- To Determine the Effects of Avosentan on Doubling of Serum Creatinine, End Stage Renal Disease and Death in Diabetic NephropathyTerminatedNCT00120328Phase 3
- Study to Evaluate the Effect of Renal Function on the Single-Dose Pharmacokinetics of BAY 43-9006CompletedNCT00119639Phase 1
- Maximal Dose of Angiotensin Converting Enzyme (ACE) Inhibitor for Treatment of Diabetic Kidney DiseaseCompletedNCT00118976Not applicable
- Study to Evaluate Effectiveness of Aranesp®CompletedNCT00117130Phase 4
- Evaluating Aranesp® in Subjects With End Stage Renal Disease onChronic HemodialysisCompletedNCT00117104Phase 4
- Aranesp® Monthly Preference Study - 2CompletedNCT00117078Phase 4
- SENSOR: Study to Investigate Cinacalcet Treatment in Haemodialysis Patients With Secondary HyperparathyroidismCompletedNCT00117052Phase 3
- Treatment for Subjects With Chronic Kidney Disease Receiving HaemodialysisCompletedNCT00116701Phase 3
- Epidemiologic Data of Patients in a Teaching HospitalCompletedNCT00114335
- Cinacalcet Study to Reach Kidney Disease Outcomes Quality Initiative (K/DOQI) LevelsCompletedNCT00113958Phase 2
- Study for Subjects With Chronic Kidney Disease(CKD) Not Receiving DialysisCompletedNCT00112008Phase 3
- Treatment for Subjects With Chronic Kidney Disease (CKD) Not Receiving DialysisCompletedNCT00111098Phase 3
- Treatment for Patients With Secondary Hyperparathyroidism of End-Stage Renal Disease (ESRD)CompletedNCT00110929Phase 2
- Safety of Single Doses of Peginesatide in Patients With Chronic Kidney DiseaseTerminatedNCT00109291Phase 2
- Using the Drug Spironolactone to Test If It Reduces Protein Leakage From the KidneyCompletedNCT00106561Phase 2/3
- Study of FK778 in Renal Transplant Recipients With Untreated BK NephropathyTerminatedNCT00104338Phase 2
- Study of the Safety of FG-3019 in Incipient Nephropathy Due to Type 1 or Type 2 Diabetes MellitusCompletedNCT00102297Phase 1
- Safety and Efficacy of Aliskiren When Added to Standardized Losartan and Optimal Antihypertensive Therapy in Patients With Hypertension, Type 2 Diabetes and ProteinuriaCompletedNCT00097955Phase 2
- Safety and Pharmacokinetics of Single Intravenous Doses of Peginesatide in Healthy VolunteersCompletedNCT00097747Phase 1
- A Study in Children With Growth Failure Due to Chronic Renal Insufficiency (CRI) or End Stage Renal Disease (ESRD)CompletedNCT00097617
- Study Evaluating Darbepoetin Alfa in Subjects With Chronic Kidney Disease (CKD) Receiving DialysisCompletedNCT00096915Phase 3
- Cinacalcet HCl in Chronic Kidney Disease Subjects With Secondary Hyperparathyroidism Not Receiving DialysisCompletedNCT00094484Phase 3
- Study to Assess Darbepoetin Alfa in Subjects With Chronic Kidney DiseaseCompletedNCT00093977Phase 3
- Zemplar® Capsule in Reducing Serum Intact Parathyroid Hormone Levels in Chronic Kidney Disease Stage 5 Subjects on Hemodialysis or Peritoneal DialysisCompletedNCT00091975Phase 3